IMMUNOPROPHYLAXIS OF SEVERE RESPIRATORY-SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA: RESULTS OF 4 EPIDEMIC SEASONS

IMMUNOPROPHYLAXIS OF SEVERE RESPIRATORY-SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA: RESULTS OF 4 EPIDEMIC SEASONS

Children with bronchopulmonary dysplasia belong to the risk group of severe respiratory-syncytial viral infection (RSV). World experience and authors' own clinical data show that seasonal immunoprophylaxis of RSV infection's severe course by palivizumab in these patients allows reducing fr...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Baranov, I. V. Davydova, T. V. Turti, L. S. Namazova-Baranova, V. V. Altunin, E. P. Zimina, E. V. Pavlyukova
Format:	Article
Language:	Russian
Published:	Union of pediatricians of Russia 2012-12-01
Series:	Педиатрическая фармакология
Subjects:	respiratory-syncytial virus bronchopulmonary dysplasia acute respiratory viral infection respiratory function palivizumab
Online Access:	https://www.pedpharma.ru/jour/article/view/268
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunoprophylaxis of Respiratory Syncytial Virus Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

PREVENTIVE STRATEGIES IN THE STAGES OF FORMATION AND COURSE OF BRONCHOPULMONARY DYSPLASIA
by: I. V. Davydova, et al.
Published: (2014-03-01)

MUCOLYTICS IN BRONCHOPULMONARY DYSPLASIA THERAPY
by: I. V. Davydova, et al.
Published: (2012-10-01)

Respiratory Syncytial Virus Lower Respiratory Tract Infections in Premature Infants and Infants with Bronchopulmonary Dysplasia
by: D. Yu. Ovsyannikov, et al.
Published: (2015-10-01)

Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia
by: Juan Gabriel Piñeros, et al.
Published: (2021-11-01)

Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region
by: Adel S. Alharbi, et al.
Published: (2024-09-01)

Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
by: Andreea Calomfirescu-Avramescu, et al.
Published: (2025-02-01)

Modern Approaches in management of Children with Acute Bronchiolitis
by: Alexander A. Baranov, et al.
Published: (2020-02-01)

FUNCTIONAL ASSESSMENT OF RESPIRATORY DISORDERS IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA DURING FOLLOW-UP
by: I. V. Davydova, et al.
Published: (2014-11-01)

Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant
by: Teresa Jackowska, et al.
Published: (2024-12-01)

IMMUNOPTOPHYLAXIS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN UNDER RISK OF HEAVY COURSE OF THE DISEASE: PRELIMINARY RESULTS OF IMPLEMENTING THE MOSCOW PROGRAM
by: A. A. Korsunskiy, et al.
Published: (2012-06-01)

Clinical course of children with postinfectious bronchiolitis obliterans with versus without comorbid bronchopulmonary dysplasia
by: Lamia Medghoul, et al.
Published: (2025-07-01)

Respiratory syncytial virus immunization in children: The old, the new and what’s just around the corner
by: Bosco A. Paes, et al.
Published: (2025-12-01)

Respiratory syncytial virus immunization patterns in Germany, 2015–2020
by: Moritz Wick, et al.
Published: (2024-12-01)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
by: Tianzhou Yu, et al.
Published: (2024-03-01)

A CLINICAL AND ECONOMICAL ANALYSIS OF THE RESULTS PRODUCED BY THE PROGRAM OF RSV-INFECTION PROPHYLAXIS DURING THE EPIDEMIOLOGICAL SEASON OF 2012/2013 IN MOSCOW
by: V. I. Ignat'eva, et al.
Published: (2013-11-01)

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro
by: Envera Lekic, et al.
Published: (2024-05-01)

Evaluation of melatonin efficacy in prevention of bronchopulmonary dysplasia in preterm newborn infants
by: Manizheh Mostafa Gharehbaghi, et al.
Published: (2022-02-01)

Effect of an In-Home Palivizumab Administration Program for Children with Medical Complexity
by: Hina Emanuel, et al.
Published: (2024-09-01)

Update to: Study Pre-protocol for “BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study” [version 4; peer review: 3 approved, 1 approved with reservations]
by: Mark D. Lyttle, et al.
Published: (2024-12-01)

Immunoprophylaxis of infectious diseases in premature infants
by: Alexander A. Baranov, et al.
Published: (2018-12-01)

Intratracheal administration of budesonide with surfactant in very low birth weight infants to prevent bronchopulmonary dysplasia
by: Minji Heo, et al.
Published: (2020-08-01)

Metabolic acidosis as a risk factor for bronchopulmonary dysplasia in preterm infants born between 23 + 0 and 31 + 6 weeks of gestation: a retrospective case-control study
by: T. W. Shin, et al.
Published: (2025-06-01)

Bronchopulmonary Dysplasia in Post-Surfactant Era: Results of an Objective Assessment of the Disease
by: I. V. Davydova, et al.
Published: (2015-09-01)

Cost effectiveness of a protocol using palivizumab in preterm infants
by: Yolanda Hernández-Gago, et al.
Published: (2017-03-01)

ACUTE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN CHILDREN IN THE AGE ASPECT
by: V. B. Rovny, et al.
Published: (2015-08-01)

Advancements in biomarkers and machine learning for predicting of bronchopulmonary dysplasia and neonatal respiratory distress syndrome in preterm infants
by: Hanieh Talebi, et al.
Published: (2025-04-01)

Extrapulmonary Conditions, Concomitant of Bronchopulmonary Dysplasia, in Babies of the First 3 Years of Life: Results of a Retrospective Cross-Sectional Study
by: K. A. Kazakova, et al.
Published: (2016-12-01)

CLINICAL AND PATHOMORPHOLOGICAL MANIFESTATIONS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION. CASE REPORT
by: I. V. Babachenko, et al.
Published: (2018-04-01)

Genetic Determination of Bronchopulmonary Dysplasia Formation: Pros and Cons
by: V. K. Pozharishchenskaya, et al.
Published: (2017-05-01)

The Impact of Palivizumab for Respiratory Syncytial Virus Prophylaxis on Preschool Childhood Asthma
by: Hannah Ora Hasson, et al.
Published: (2024-11-01)

IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE
by: E. S. Keshishyan
Published: (2013-07-01)

Improving the quality of care of respiratory syncytial virus in the neonatal and pediatric populations globally
by: Fungwe Jah, et al.
Published: (2025-05-01)

MUCOLYTIC THERAPY IN INFANTS
by: I. V. Davydova, et al.
Published: (2013-09-01)

Circulation of Respiratory Syncytial Virus (RSV) in Poland Between Seasons of 2009/2010 and 2022/2023 Based on SENTINEL System
by: Karol Szymański, et al.
Published: (2025-01-01)

Characteristics of respiratory syncytial virus infection in children in Pudong New Area， Shanghai， 2013‒2023
by: YU Qiumiao, et al.
Published: (2025-05-01)

Epidemiology and genetic diversity of human respiratory syncytial virus in Belgium between 2011 and 2019
by: Kaat Ramaekers, et al.
Published: (2024-10-01)

Assessment of Safety, Immunogenicity and Preventive Efficacy of Prevenar-13 in Children with Bronchopulmonary Dysplasia
by: E. S. Zubova, et al.
Published: (2018-04-01)

THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS
by: A. V. Rudakova, et al.
Published: (2012-07-01)

Respiratory pathogen trends in patients with Kawasaki disease during the COVID-19 pandemic and respiratory syncytial virus epidemic in Japan
by: Takahiro Namba, et al.
Published: (2023-09-01)